ATI D1
Alternative Names: Anti-JAG1 antibody - Alanis Therapeutics; ATI-D1Latest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator AvantGen
- Class Antibodies; Antineoplastics
- Mechanism of Action Jagged-1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 31 Dec 2024 Alanis Therapeutics plans phase-I/II trial for the treatment of Myelodysplastic syndromes and acute myeloid leukemia
- 17 Dec 2024 Pharmacodynamics data from preclinical trial in Myelodysplastic syndromes and Acute myeloid leukemia released by Alanis Therapeutics (Alanis Therapeutics website; December 2024)
- 09 Dec 2024 Preclinical trials in Myelodysplastic syndromes in USA (Parenteral)